spacer
home > ebr > summer 2003 > making the remarkable routine
PUBLICATIONS
European Biopharmaceutical Review

Making the Remarkable Routine

Mass spectrometry (MS) has become one of the most ubiquitous analytical techniques in use today. It represents a powerful tool in the study of all substances because it provides more information about the composition and structure of a substance from a smaller amount of sample than any other analytical technique.

Of all the MS techniques currently available, fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS) is arguably the most powerful. It offers 10-100 times higher mass resolution, mass resolving power and mass accuracy than any other mass analysis technique. Alternatively, viewed only as a separation device, ultrahigh-resolution FT-ICR MS offers more than 100 times higher peak capacity than the most effective wet chemical separation methods. This makes it possible to analyse complex mixtures with no prior chromatography.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Professor Alan Marshall, National High Magnetic Field Laboratory at Florida State University, USA and Dr Alan Street, Oxford Instruments Superconductivity, at Oxford Instruments, UK

Professor Alan G Marshall received his BA in Chemistry from Northwestern University and PhD in Physical Chemistry from Stanford University. Following faculty positions at University of British Columbia and Ohio State University, he moved to Florida State University in 1993, where he is Kasha Professor of Chemistry and Director of the Ion Cyclotron Resonance Program at the National High Magnetic Field Laboratory. He is best known for his co-invention and continuing leading development of fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry.

His recognitions include Fellow in the American Physical Society and the American Association for the Advancement of Science; three national awards from the American Chemical Society; and awards from the Spectroscopy Society of Pittsburgh, the American Society for Mass Spectrometry and the International Society for Mass Spectrometry. In addition Professor Marshall is widely published.


Dr Alan Street gained a degree in Physics from the University of Wales and a DPhil from the University of York. His working life has focused on the development and exploitation of technology, having started in 1975 with GEC at their Hirst Research Centre in Wembley.

He moved to Marconi Elliot Avionics at Boreham Wood and then on to Sperry Gyroscope in Bracknell to join a team developing a new navigational technology based on laser gyroscopes. Joining Oxford Instruments Superconductivity in 1982, Alan is now Technical Director and Deputy Managing Director.


spacer
Professor Alan G Marshall
spacer
spacer
spacer
Dr Alan Street
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement